Family history is an important risk factor, if you have one.
But most of us don’t have a family history of ovarian cancer.
geneType™ for Ovarian Cancer is for:
Our reports help you and your healthcare provider translate your personal clinical, family and genetic data into an actionable prevention health plan.
Your test results include a patient summary to highlight the most important take-home messages.
To order online through our patient portal, follow these four simple steps to be connected with a third-party telehealth provider.
Register for your geneType™ test using our portal.
Depending on the test, you may require access to your medical records (ex. lipid panel or breast density results).
Payment will be collected at time of registration.
Your clinical information will be reviewed by our third party telehealth partner, DNA Visit.
If you qualify for testing, a kit will be shipped to your address on file.
If you do not qualify for testing, you will receive a refund.
Complete buccal sample collection as instructed and return in pre-paid envelope.
Do not eat, drink, smoke, vape or chew gum within 30 minutes of collection.
When your results are ready, you will have the chance to speak with your DNA Visit healthcare provider.
All at-risk patients will be required to speak with the provider prior to results-release.
If your question is not shown here, please Contact us directly.
No. This risk assessment does not test for hereditary breast and ovarian cancer (HBOC), or any other hereditary cancer syndrome. geneType™ is a risk assessment for asymptomatic women in the general population who are either ineligible for HBOC testing, or who have come back as negative carriers following HBOC testing.
geneType™ for Ovarian Cancer combines several of risk factor, such as age, family history, and your DNA markers, into one comprehensive risk assessment.
geneType™ for Ovarian Cancer is for women aged 40 years or older.
No. This test is not applicable to women who have a personal history of ovarian cancer or who have already been shown to have an HBOC mutation, for example in the BRCA1 or BRCA2 gene, or a diagnosis of a genetic syndrome that may be associated with elevated risk of ovarian cancer.
*Patient eligibility dependent on personal medical history, age and sex
The Multi-Risk suite of tests is for adults 40-85 years of age. At maximum, a woman would be eligible for eight diseases in the panel; a man would be eligible for seven. Starting at age 30, a patient may qualify for geneType’s™ cancer risk assessments only.
Accredited For Compliance With NPAAC Standards And ISO 15189